Comparison of Metabolic and Anatomic Response to Chemotherapy Based on PERCIST and RECIST in Patients with Advanced Stage Non-small Cell Lung Cancer |
Ordu, Cetin
(Department of Internal Medicine, Faculty of Medicine, Bilim University)
Selcuk, Nalan A. (Department of Nuclear Medicine, Yeditepe University Hospital) Akosman, Cengiz (Medical Oncology Section, Department of Internal Medicine, Yeditepe University Hospital) Eren, Orhan Onder (Medical Oncology Section, Department of Internal Medicine, Yeditepe University Hospital) Altunok, Elif C. (Department of Biostatistics, Yeditepe University Hospital) Toklu, Turkay (Department of Nuclear Medicine, Yeditepe University Hospital) Oyan, Basak (Medical Oncology Section, Department of Internal Medicine, Yeditepe University Hospital) |
1 | Dwamena BA, Sonnad SS, Angobaldo JO, et al (1999). Metastases from non-small cell lung cancer: Mediastinal staging in the 1990s-meta-analytic comparison of PET and CT. Radiology, 213, 530-36. DOI ScienceOn |
2 | Eisenhauer EA, Therasse P, Bogaerts J, et al (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45, 228-47. DOI |
3 | Hasbek Z, Yucel B, Salk I, et al (2014). Potential impact of atelectasis and primary tumor glycolysis on F-18 FDG PET/CT on survival in lung cancer patients. Asian Pac J Cancer Prev, 15, 4085-9. 과학기술학회마을 DOI |
4 |
Hoekstra CJ, Stroobants SG, Smit EF, et al (2005). Prognostic relevance of response evaluation using [ |
5 | Jemal A, Bray F, Center MM (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. DOI |
6 |
Lee DH, Kim SK, Lee HY, et al (2009). Early prediction of response to first-line therapy using integrated |
7 | Mac Manus MP, Hicks RJ, Matthews JP, et al (2003). Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol, 21, 1285-92. DOI |
8 | Martin J, Ginsberg RJ, Venkatraman ES, et al (2002). Long-term results of combined-modality therapy in resectable nonsmall-cell lung cancer. J Clin Oncol, 20, 1989-95. DOI |
9 | Miranda E, Bianchi P, Destro A, et al (2013). Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases. Cancer, 119, 266-76. DOI |
10 |
Nahmias C, Hanna WT, Wahl LM, et al (2007). Time course of early response to chemotherapy in non-small cell lung cancer patients with |
11 |
Novello S, Vavala T, Levra MG, et al (2013). Early response to chemotherapy in patients with non-small-cell lung cancer assessed by [ |
12 | Sekine I, Tamura T, Kunitoh H, et al (1999). Progressive disease rate as a surrogate endpoint of phase II trials fornon-smallcell lung cancer. Ann Oncol, 10, 731-3. DOI |
13 | Suzuki C, Jacobsson H, Hatschek T, et al (2008). Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics, 28, 329-44. DOI |
14 | Vansteenkiste J, Fischer BM, Dooms C, et al. (2004). Positronemission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol, 5, 531-40. DOI |
15 | Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009). From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med, 50, 122-50. DOI ScienceOn |
16 | Weber WA, Figlin R (2007). Monitoring cancer treatment with PET/CT: does it make a difference? J Nucl Med, 48, 36-44. |
17 | Weber WA, Petersen V, Schmidt B, et al (2003). Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol, 21, 2651-7. DOI |
18 | Cerfolio RJ, Ojha B, Bryant AS, et al (2004). The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with non-small cell lung cancer. Ann Thorac Surg, 78, 1017-23. DOI |
19 | Azzoli CG, Temin S, Aliff T, et al (2011). Focused update of 2009 American society of clinical oncology American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol, 29, 3825-31. DOI |
20 | Birchard KR, Hoang JK, Herndon JE Jr, et al (2009). Early changes in tumor size in patients treated for advanced stage non-small cell lung cancer do not correlate with survival. Cancer, 115, 581-6. DOI |
21 | De Geus-Oei LF, van der Heijden HF, Visser EP, et al (2007). Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer. Nucl Med, 48, 1592-98. DOI |
22 | Ding Q, Cheng X, Yang L, et al (2014). PET/CT evaluation of response to chemotherapy in non-small cell lung cancer: PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST). J Thorac Dis, 6, 677-83. |
![]() |